UBS Reiterates Buy on Esperion Therapeutics (ESPR) Ahead of FDA Meeting; Sees Meaningful Upside
Tweet Send to a Friend
UBS analyst Andrew Peters reiterated his Buy rating and $140 price target on Esperion Therapeutics (NASDAQ: ESPR), which suggests 152 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
